Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

被引：0
|
作者：
Burotto, Mauricio
Powles, Thomas
Escudier, Bernard
Apolo, Andrea B.
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
George, Saby
Scheffold, Christian
Wang, Peter
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
机构：
[1] Bradford Hill Clin Res Ctr, Santiago, Chile
[2] Barts Canc Ctr, London, England
[3] Royal Free London NHS Fdn Trust, London, England
[4] Gustave Roussy, Villejuif, France
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med Nutr, Mexico City, Mexico
[7] MD Anderson Canc Ctr, Houston, TX USA
[8] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Univ Pavia, Pavia, Italy
[10] Ctr Pesquisa Oncol, Porto Alegre, Brazil
[11] Inst Oncol Cordoba, dn Richardet Longo, Cordoba, Argentina
[12] Westmead Hosp, Sydney, NSW, Australia
[13] Macquarie Univ, Sydney, NSW, Australia
[14] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[16] Eberhard Karls Univ Tubingen, Tubingen, Germany
[17] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[18] Exelixis Inc, Alameda, CA USA
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] Mem Sloan Kettering Canc Ctr, New York, NY USA
[21] Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Boston, MA USA
[22] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
603
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
  • [2] Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
    Powles, T.
    Burotto, M.
    Escudier, B.
    Apolo, A. B.
    Bourlon, M. T.
    Shah, A. Y.
    Suarez, C.
    Porta, C.
    Barrios, C. H.
    Richardet, M.
    Gurney, H.
    Kessler, E. R.
    Tomita, Y.
    Bedke, J.
    George, S.
    Scheffold, C.
    Wang, P.
    Fedorov, V.
    Motzer, R. J.
    Choueiri, T. K.
    ESMO OPEN, 2024, 9 (05)
  • [3] Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Powles, Thomas
    Burotto, Mauricio
    Apolo, Andrea B.
    Escudier, Bernard
    McDermott, David F.
    Braun, David A.
    Han, Celine
    Lee, George
    Dwivedi, Bhakti
    Li, Jun
    Gupta, Saurabh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Zurawski, B.
    Oyervides Juarez, V. M.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Barrios, C. H.
    Richardet, M.
    Pook, D.
    Tomita, Y.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Apolo, A. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159
  • [5] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Benjamin Duy Tran
    Jing Li
    Neang Ly
    Raffaella Faggioni
    Lorin Roskos
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
  • [6] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
    Motzer, Robert J.
    Escudier, Bernard
    Burotto, Mauricio
    Powles, Thomas
    Apolo, Andrea B.
    Bourlon, Maria T.
    Shah, Amishi Yogesh
    Porta, Camillo
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin Eduardo
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    Rangwala, Fatima A.
    Askelson, Margarita
    Panzica, Julie
    Fedorov, Viktor
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [7] First-line nivolumab plus cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Porta, C. G.
    Burotto, M.
    Suarez Rodriguez, C.
    Bourlon, M. T.
    Hsieh, J.
    Shah, A. Y.
    Hamzaj, A.
    Bedke, J.
    Pook, D.
    Kessler, R.
    Tomita, Y.
    Drakaki, A.
    Zhang, J.
    Simsek, B.
    Schwab, G.
    Escudier, B.
    Motzer, R. J.
    Choueiri, T. K.
    Apolo, A. B.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S688 - S689
  • [8] Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.
    Cella, David
    Choueiri, Toni K.
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Zhang, Joshua
    Ivanescu, Cristina
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Tran, Benjamin Duy
    Li, Jing
    Ly, Neang
    Faggioni, Raffaella
    Roskos, Lorin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189
  • [10] Nivolumab plus cabozantinib (N plus C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Pook, David
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria T.
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Y.
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    Apolo, Andrea B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 131 - 131
12345